Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received
accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease …

Data-driven disease progression models are an emerging set of computational tools that
reconstruct disease timelines for long-term chronic diseases, providing unique insights into …

Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by both
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …

In early Alzheimer's disease (AD) β-amyloid (Aβ) deposits throughout association cortex and
tau appears in the entorhinal cortex (EC). Why these initially appear in disparate locations is …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …

Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal,
ie slowing of Alzheimer's disease (AD) progression. However, antibody therapy may not be …

The cause of Alzheimer's disease (AD), and the pathophysiological mechanisms involved,
remain major unanswered questions in medical science. Oral bacteria, especially those …

Toxic amyloid-beta (Aβ) plaque and harmful inflammation are two leading symptoms of
Alzheimer's disease (AD). However, precise AD therapy is unrealizable due to the lack of …

It is well-established that women are disproportionately affected by Alzheimer's disease. The
mechanisms underlying this sex-specific disparity are not fully understood, but several …